In Brief: Genetics Institute/Johns Hopkins
This article was originally published in The Gray Sheet
Executive SummaryGenetics Institute/Johns Hopkins: Form Metamorphix, Inc. to develop and commercialize transforming growth factor-beta (TGF~) genes, which are involved in cell growth and differentiation. GI, a unit of American Home Products, will contribute $3.6 mil. in exchange for 58% of the new company. GI is conducting pilot clinical trials on one type of TGF~ gene it discovered, bone morphogenic proteins, for treating tibia and maxillofacial bone fractures, and for use in spinal reconstruction. The latter trial is part of a four-year, $50 mil. collaboration with Sofamor Danek announced earlier this year ("The Gray Sheet" Feb. 20, I&W-2)...
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.